Completing data — refresh the page later to see the latest
68538-85-2Nc1nc2c(c(=O)[nH]1)N(C=O)[C@@H](CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2VVIAGPKUTFNRDU-STQMWFEESA-N(6S)-5-formyltetrahydrofolic acid is the pharmacologically active (6S)-stereoisomer of 5-formyltetrahydrofolic acid. It has a role as a metabolite and an antineoplastic agent. It is a conjugate acid of a (6S)-5-formyltetrahydrofolate(2-).
Breast Feeding; Lactation; Milk, Human; Antidotes; Vitamin B Complex; Vitamins
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
As leucovorin is a derivative of folic acid, it can be used to increase levels of folic acid under conditions favoring folic acid inhibition (following treatment of folic acid antagonists such as methotrexate). Leucovorin enhances the activity of fluorouracil by stabilizing the bond of the active metabolite (5-FdUMP) to the enzyme thymidylate synthetase.
Drug Induced Liver Injury Rank (DILIrank 2.0)
Levoleucovorin
vNo-DILI-concern
0
No match
DOI:10.1016/j.drudis.2016.02.015
Levoleucovorin is actively and passively transported across cell membranes. In vivo, levoleucovorin is converted to 5-methyltetrahydrofolic acid (5-methyl-THF), the primary circulating form of active reduced folate. Levoleucovorin and 5-methyl-THF are polyglutamated intracellularly by the enzyme folylpolyglutamate synthetase. Folylpolyglutamates are active and participate in biochemical pathways that require reduced folate.
Folic acid is an essential B vitamin required by the body for the synthesis of purines, pyrimidines, and methionine before incorporation into DNA or protein. However, in order to function in this role, it must first be reduced by the enzyme dihydrofolate reductase (DHFR) into the cofactors dihydrofolate (DHF) and tetrahydrofolate (THF). This important pathway, which is required for de novo synthesis of nucleic acids and amino acids, is disrupted when high-dose methotrexate is used for cancer therapy. As methotrexate functions as a DHFR inhibitor to prevent DNA synthesis in rapidly dividing cells, it also prevents the formation of DHF and THF. This results in a deficiency of coenzymes and a resultant buildup of toxic substances that are responsible for numerous adverse side effects of methotrexate therapy. As levoleucovorin and leucovorin are analogs of tetrahydrofolate (THF), they are able to bypass DHFR reduction and act as a cellular replacement for the co-factor THF, thereby preventing these toxic side effects.
Extensively converted to tetrahydrofolic derivatives.
Hepatic and intestinal mucosal, the main metabolite being the active 5-methyltetrahydrofolate. Leucovorin is readily converted to another reduced folate, 5,10-methylenetetrahydrofolate, which acts to stabilize the binding of fluorodeoxyridylic acid to thymidylate synthase and thereby enhances the inhibition of this enzyme. Half Life: 6.2 hours
68538-85-2DTXSID4023204CHEMBL1908841CHEBI:63606990S25980Y
LEVOLEUCOVORIN
Established Pharmacologic Class [EPC] - Folate Analog
Chemical Structure [CS] - Folic Acid
Levoleucovorin is a Folate Analog.
LEVOLEUCOVORIN
After rapid intravenous administration, serum total tetrahydrofolate (total-THF) concentrations reached a mean peak of 1722 ng/mL. Serum (6S)-5-methyl-5,6,7,8-tetrahydrofolate concentrations reached a mean peak of 275 ng/mL and the mean time to peak was 0.9 hours.
Urinary.
Data can't be found.
Data can't be found.
For the treatment of osteosarcoma (after high dose methotrexate therapy). Used to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists, and to treat megaloblastic anemias due to folic acid deficiency. Also used in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. Used in cancer chemotherapy involving the drug methotrexate.
UsesLevoleucovorin (Levofolinic acid) is the pharmacologically active levoisomer of racemic leucovorin. Levoleucovorin can be used as a rescue agent after high-dose Methotrexate (HY-14519) therapy, and in combination with fluorouracil for the research of advanced metastatic colorectal cancer[1].
DefinitionChEBI: The pharmacologically active (6S)-stereoisomer of 5-formyltetrahydrofolic acid.